Clinical Trial Detail

NCT ID NCT03829501
Title Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Kymab Limited
Indications

melanoma

non-small cell lung carcinoma

kidney cancer

stomach cancer

hepatocellular carcinoma

cervical cancer

triple-receptor negative breast cancer

pancreatic cancer

esophageal cancer

head and neck squamous cell carcinoma

Therapies

Atezolizumab + KY1044

KY1044

Age Groups: adult senior

Additional content available in CKB BOOST